Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Moderna, Inc.    MRNA

MODERNA, INC.

(MRNA)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 07/16 09:53:21 am
83.775 USD   +4.43%
06:32aJ&J raises forecast after quarterly profit beats estimates
RE
06:21aJ&J raises forecast after quarterly profit beats estimates
RE
06:16aJ&J raises forecast after quarterly profit beats estimates
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Temasek-led investor group in $250 million vaccine bet on Germany's BioNTech

share with twitter share with LinkedIn share with facebook
06/29/2020 | 10:52am EDT
FILE PHOTO: The headquarters of biopharmaceutical company BioNTech are seen in Mainz

By Ludwig Burger

Singapore's state investor Temasek and other investors are injecting $250 million into German biotech company BioNTech, which is developing an experimental vaccine against the coronavirus with pharmaceutical giant Pfizer.

The investment, which BioNTech said was via a private placement, reflects heightened investor interest in the race to develop an agent that will stop the pandemic and sent shares in biotech firms such as Moderna and Novavax soaring this year.

U.S.-listed shares in the German company jumped almost 15% to their highest since March 19 on the news. They have surged more than 80% so far this year against the Nasdaq biotech index's gain of 12%.

BioNTech, which went public on Nasdaq in October last year, said the investors would purchase about $139 million in ordinary shares and $112 million in 4-year mandatory convertible notes.

It has said it expects first clinical data on its COVID-19 vaccine development programme known as BNT162 this month or in July.

The transaction would increase the number of BioNTech shares outstanding by 2.6 million from 226.8 million shares as per end of March, resulting in a combined stake of 1.1% for the investor group once all notes are converted.

BioNTech, which is also working on personalised cancer vaccines, would not say how much of the total is attributed to Temasek. Temasek would also not comment.

The investment adds to Temasek's healthcare assets that include Singapore biotech firm and COVID-19 treatment developer Tychan, British biotech firm Orchard Therapeutics and Irish drug delivery firm Aerogen.

Life sciences and agribusiness made up 7% of Temasek's holdings in the year to March 2019, up from 3% in the year to 2015.

BioNTech and Pfizer launched testing programmes involving humans in April and May.

Domestic rival vaccine developer CureVac, in which the German government is taking a 23% stake, is planning an initial public offering in the United States next month. U.S. peer Translate Bio has attracted France's Sanofi as an investor in a deal worth as much as $2 billion.

BioNTech, which awarded the rights to BNT162 in China to Shanghai Fosun under a March collaboration deal, is competing with CureVac as well as U.S. biotech firms Moderna and Translate Bio in the race to develop messenger-RNA vaccines.

(Additional reporting by Anshuman Daga in Singapore and Thyagaraju Adinarayan in London; editing by Thomas Seythal and Emelia Sithole-Matarise)

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 1.48% 78.6025 Delayed Quote.130.22%
MODERNA, INC. -0.22% 80.465 Delayed Quote.310.12%
NASDAQ COMP. -1.14% 10448.766868 Delayed Quote.17.59%
NOVAVAX, INC. -0.08% 111.6 Delayed Quote.2,692.71%
PFIZER LIMITED -0.97% 4139.75 End-of-day quote.-2.00%
PFIZER, INC. -0.59% 35.49 Delayed Quote.-10.08%
SANOFI SA 0.10% 93.8 Real-time Quote.4.52%
SHANGHAI FOSUN PHARMACEUTICAL GROUP CO., LTD. 9.99% 42.83 End-of-day quote.61.02%
SHANGHAI STOCK EXCHANGE B SHARES INDEX -3.58% 229.2354 Real-time Quote.-7.43%
TRANSLATE BIO, INC. -0.67% 18.57 Delayed Quote.133.29%
share with twitter share with LinkedIn share with facebook
Latest news on MODERNA, INC.
06:32aJ&J raises forecast after quarterly profit beats estimates
RE
06:21aJ&J raises forecast after quarterly profit beats estimates
RE
06:16aJ&J raises forecast after quarterly profit beats estimates
RE
05:08aS.African rand slips as weak China data overshadows vaccine hope
RE
01:08aShares fall as Sino-U.S. tensions eclipse China GDP growth
RE
07/15Australia shares flat as surging COVID-19 cases offset vaccine cheer
RE
07/15MODERNA : Advances on Covid-19 vaccines looking like only hope in US
AQ
07/15Dollar nurses losses as investors wait for China data
RE
07/15Stocks rally on vaccine hopes, crude oil gains
RE
07/15MODERNA : TSX climbs to highest close since March on COVID-19 vaccine hopes
AQ
More news
Financials (USD)
Sales 2020 114 M - -
Net income 2020 -530 M - -
Net cash 2020 1 752 M - -
P/E ratio 2020 -55,8x
Yield 2020 -
Capitalization 31 191 M 31 191 M -
EV / Sales 2019
EV / Sales 2020 259x
Nbr of Employees 850
Free-Float 79,7%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 15
Average target price 91,67 $
Last Close Price 80,22 $
Spread / Highest target 67,0%
Spread / Average Target 14,3%
Spread / Lowest Target -25,2%
EPS Revisions
Managers
NameTitle
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
Noubar B. Afeyan Chairman
David W. Meline Chief Financial Officer
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.310.12%31 191
LONZA GROUP59.23%44 273
SEATTLE GENETICS, INC.55.69%30 793
IQVIA HOLDINGS INC.-1.39%29 097
INCYTE CORPORATION19.39%22 661
ALNYLAM PHARMACEUTICALS, INC.37.21%18 229